Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oncoclínicas do Brasil Serviços Médicos S.A. (ONCO3.SA)
São Paulo, SP, BR
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, chemotherapy, oral chemotherapy, and prostate cancer hormone therapy; and surgery procedures, such as breast, head and neck, lung, prostate cancer, stomach, bladder cancer, oncological, kidney cancer, gynecological, and testicular cancer. It also provides diagnostics services comprising pathological analysis, genetic testing, molecular journey, personalized medicine and individualized treatment, myelogram-bone marrow biopsy, and ONCO test-PDO. In addition, the company offers treatment support services, which include veinviewer, cryotherapy, integrative medicine, and DeLife, as well as hilotherapy, laser therapy, OC care line, OC precision medicine, OncoACCESS, survivorship, and telemedicine services. Oncoclínicas do Brasil Serviços Médicos S.A. was founded in 2010 and is headquartered in São Paulo, Brazil.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +17.92% | +5.93% | -27.33% | -55.99% | -26.90% | -54.04% | -74.39% | -88.53% | -91.54% | -91.54% | -91.54% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 4 | 0 |
| Sell | 3 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%-7.8% Q1'26: -22.3% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%-412.4% Q1'26: -64.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%-62.9% Q1'26: -20.8% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%-44.0% Q1'26: -9.8% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%-58.1% Q1'26: -10.5% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+9.4% Q1'26: +47.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×-1.70× Q1'26: -23.37× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
2.70B
est: 2.72B (-0.6%)
|
4.09B
est: 4.11B (-0.4%)
|
5.49B
est: 5.86B (-6.4%)
|
6.23B
est: 6.27B (-0.7%)
|
5.74B
est: 5.80B (-1.0%)
|
5.93B
5.80B – 6.02B
+2.3% YoY
|
6.31B
5.85B – 6.56B
+6.3% YoY
|
6.10B
5.80B – 6.27B
-3.3% YoY
|
| EBITDA |
343.67M
est: 335.54M (+2.4%)
|
693.17M
est: 506.72M (+36.8%)
|
1.12B
est: 182.81M (+512.5%)
|
271.24M
est: 195.50M (+38.7%)
|
-2.23B
est: 180.86M (-1,332.4%)
|
185.06M
180.97M – 187.74M
+2.3% YoY
|
196.67M
182.31M – 204.60M
+6.3% YoY
|
190.12M
180.90M – 195.42M
-3.3% YoY
|
| EBIT |
216.70M
est: 204.18M (+6.1%)
|
518.01M
est: 308.35M (+68.0%)
|
862.31M
est: -99.69M (+965.0%)
|
-55.14M
est: -106.61M (+48.3%)
|
-2.53B
est: -98.63M (-2,461.4%)
|
-100.92M
-102.38M – -98.69M
-2.3% YoY
|
-107.25M
-111.58M – -99.42M
-6.3% YoY
|
-103.68M
-106.57M – -98.65M
+3.3% YoY
|
| Net Income |
-46.90M
est: 35.29M (-232.9%)
|
46.26M
est: 58.87M (-21.4%)
|
223.62M
est: 233.22M (-4.1%)
|
-646.19M
est: 72.71M (-988.7%)
|
-3.62B
est: -3.62B (+0.0%)
|
42.91M
40.75M – 45.07M
+101.2% YoY
|
129.54M
73.21M – 185.88M
+201.9% YoY
|
73.16M
69.47M – 76.84M
-43.5% YoY
|
| SGA |
688.05M
est: 668.14M (+3.0%)
|
980.82M
est: 1.01B (-2.8%)
|
1.17B
est: 1.37B (-14.5%)
|
1.40B
est: 1.47B (-4.8%)
|
1.36B
est: 1.36B (+0.3%)
|
1.39B
1.36B – 1.41B
+2.3% YoY
|
1.48B
1.37B – 1.53B
+6.3% YoY
|
1.43B
1.36B – 1.47B
-3.3% YoY
|
| EPS |
-0.10
est: 0.06 (-272.5%)
|
0.10
est: 0.09 (+7.5%)
|
0.43
est: 0.35 (+22.6%)
|
-1.05
est: 0.11 (-1,060.3%)
|
-5.38
est: -2.59 (-107.5%)
|
0.06
0.06 – 0.07
+102.5% YoY
|
0.19
0.11 – 0.28
+197.9% YoY
|
0.11
0.10 – 0.11
-42.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck Brazil Small-Cap ETF BRF | 0.21% | 48.9K | 0.60% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 320.9K | 0.06% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 27.9K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 62.9K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 3.10M | 0.06% |
| 6 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.00% | 12.6K | 0.65% |
| 7 | Vanguard Total International Stock ETF VXUS | 0.00% | 3.62M | 0.05% |
| 8 | Vanguard ESG International Stock ETF VSGX | 0.00% | 36.4K | 0.10% |
| 9 | Vanguard Total World Stock ETF VT | 0.00% | 211.8K | 0.06% |
| 10 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 5.0K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bruno Lemos Ferrari | Vice Chairman & Chief Executive Officer | — | male |
| Camille Loyo Faria | VP, CFO & Investor Relations Officer | — | female |
| Carlos Gil Moreira Ferreira | CEO & Medical Officer | — | male |
| Cristiano Affonso Ferreira de Camargo | Chief Financial and Investor Relations Officer | — | male |
| Giovane Reus Nichele da Costa | Human Resources Officer | — | male |
| Marcel Cecchi Vieira | VP of Finance, Investor Relations Officer & Director | — | male |
| Raoni Larena | Director of M&A and Operations | — | male |
| Ricardo da Silva Santoro | Chief Technology Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ONCO3.SA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
